All patients
Age < 65y (younger) Age > 65y ECOG 0 ECOG 1 Gender, female Gender, male PDL1 (TC0 and IC0 : <1% of TC and IC) PDL1 (TC1/2 or IC1/2 : ≥1% of TC or IC and <50% of TC and <10% of IC) PDL1 (TC1/2/3 or IC1/2/3 : ≥1% of TC or IC) PDL1 (TC3 or IC3 : ≥50% of TC or ≥10% of IC )
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
studies
squamous cell - mNSCLC - L1, pembrolizumab based treatment vs. all, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results KEYNOTE-407, 2018 0.64 [0.49; 0.84]
0.64 [0.49 ; 0.84 ] KEYNOTE-407, 2018 1 0% 559 NA not evaluable progression or deaths (PFS)detailed results KEYNOTE-407, 2018 0.56 [0.45; 0.70]
0.56 [0.45 ; 0.70 ] KEYNOTE-407, 2018 1 0% 559 NA not evaluable objective responses (ORR)detailed results KEYNOTE-407, 2018 2.20 [1.57; 3.09]
2.20 [1.57 ; 3.09 ] KEYNOTE-407, 2018 1 0% 559 NA not evaluable AE (any grade)detailed results KEYNOTE-407, 2018 1.20 [0.36; 3.96]
1.20 [0.36 ; 3.96 ] KEYNOTE-407, 2018 1 0% 558 NA not evaluable AE (grade 3-4)detailed results KEYNOTE-407, 2018 0.99 [0.70; 1.39]
0.99 [0.70 ; 1.39 ] KEYNOTE-407, 2018 1 0% 558 NA not evaluable AE leading to death (grade 5)detailed results KEYNOTE-407, 2018 1.31 [0.69; 2.49]
1.31 [0.69 ; 2.49 ] KEYNOTE-407, 2018 1 0% 558 NA not evaluable AE leading to treatment discontinuation (any grade)detailed results KEYNOTE-407, 2018 2.28 [1.45; 3.61]
2.28 [1.45 ; 3.61 ] KEYNOTE-407, 2018 1 0% 558 NA not evaluable AE leading to treatment discontinuation (grade 3-4)detailed results KEYNOTE-407, 2018 2.09 [1.28; 3.39]
2.09 [1.28 ; 3.39 ] KEYNOTE-407, 2018 1 0% 558 NA not evaluable TRAE leading to death (grade 5)detailed results KEYNOTE-407, 2018 1.70 [0.61; 4.75]
1.70 [0.61 ; 4.75 ] KEYNOTE-407, 2018 1 0% 558 NA not evaluable hepatitis (Autoimmune) AE (grade 3-4)detailed results KEYNOTE-407, 2018 10.24 [0.56; 188.30]
10.24 [0.56 ; 188.30 ] KEYNOTE-407, 2018 1 0% 558 NA not evaluable Alopecia AE (grade 3-4)detailed results KEYNOTE-407, 2018 0.33 [0.03; 3.22]
0.33 [0.03 ; 3.22 ] KEYNOTE-407, 2018 1 0% 558 NA not evaluable Anaemia AE (grade 3-4)detailed results KEYNOTE-407, 2018 0.72 [0.46; 1.11]
0.72 [0.46 ; 1.11 ] KEYNOTE-407, 2018 1 0% 558 NA not evaluable Arthralgia AE (grade 3-4)detailed results KEYNOTE-407, 2018 2.03 [0.37; 11.17]
2.03 [0.37 ; 11.17 ] KEYNOTE-407, 2018 1 0% 558 NA not evaluable Asthenia AE (grade 3-4)detailed results KEYNOTE-407, 2018 0.60 [0.21; 1.66]
0.60 [0.21 ; 1.66 ] KEYNOTE-407, 2018 1 0% 558 NA not evaluable Colitis AE (grade 3-4)detailed results KEYNOTE-407, 2018 2.04 [0.50; 8.23]
2.04 [0.50 ; 8.23 ] KEYNOTE-407, 2018 1 0% 558 NA not evaluable Constipation AE (grade 3-4)detailed results KEYNOTE-407, 2018 0.67 [0.11; 4.04]
0.67 [0.11 ; 4.04 ] KEYNOTE-407, 2018 1 0% 558 NA not evaluable Cough AE (grade 3-4)detailed results KEYNOTE-407, 2018 0.67 [0.11; 4.04]
0.67 [0.11 ; 4.04 ] KEYNOTE-407, 2018 1 0% 558 NA not evaluable Decreased appetite AE (grade 3-4)detailed results KEYNOTE-407, 2018 1.21 [0.37; 4.02]
1.21 [0.37 ; 4.02 ] KEYNOTE-407, 2018 1 0% 558 NA not evaluable Diarrhoea AE (grade 3-4)detailed results KEYNOTE-407, 2018 1.88 [0.69; 5.16]
1.88 [0.69 ; 5.16 ] KEYNOTE-407, 2018 1 0% 558 NA not evaluable Dyspnoea AE (grade 3-4)detailed results KEYNOTE-407, 2018 3.04 [0.31; 29.44]
3.04 [0.31 ; 29.44 ] KEYNOTE-407, 2018 1 0% 558 NA not evaluable Epistaxis AE (grade 3-4)detailed results KEYNOTE-407, 2018 1.01 [0.02; 50.94]
1.01 [0.02 ; 50.94 ] KEYNOTE-407, 2018 1 0% 558 NA not evaluable Fatigue AE (grade 3-4)detailed results KEYNOTE-407, 2018 0.82 [0.33; 2.01]
0.82 [0.33 ; 2.01 ] KEYNOTE-407, 2018 1 0% 558 NA not evaluable Hyperthyroidism AE (grade 3-4)detailed results KEYNOTE-407, 2018 2.02 [0.07; 60.40]
2.02 [0.07 ; 60.40 ] KEYNOTE-407, 2018 1 0% 558 NA not evaluable Hypophysitis AE (grade 3-4)detailed results KEYNOTE-407, 2018 4.05 [0.18; 90.23]
4.05 [0.18 ; 90.23 ] KEYNOTE-407, 2018 1 0% 558 NA not evaluable Hypothyroidism AE (grade 3-4)detailed results KEYNOTE-407, 2018 2.02 [0.07; 60.40]
2.02 [0.07 ; 60.40 ] KEYNOTE-407, 2018 1 0% 558 NA not evaluable Infusion-related reaction AE (grade 3-4)detailed results KEYNOTE-407, 2018 4.07 [0.45; 36.67]
4.07 [0.45 ; 36.67 ] KEYNOTE-407, 2018 1 0% 558 NA not evaluable Myalgia AE (grade 3-4)detailed results KEYNOTE-407, 2018 2.02 [0.18; 22.43]
2.02 [0.18 ; 22.43 ] KEYNOTE-407, 2018 1 0% 558 NA not evaluable Nausea AE (grade 3-4)detailed results KEYNOTE-407, 2018 0.75 [0.17; 3.39]
0.75 [0.17 ; 3.39 ] KEYNOTE-407, 2018 1 0% 558 NA not evaluable Neutropenia AE (grade 3-4)detailed results KEYNOTE-407, 2018 0.90 [0.61; 1.32]
0.90 [0.61 ; 1.32 ] KEYNOTE-407, 2018 1 0% 558 NA not evaluable Peripheral neuropathy AE (grade 3-4)detailed results KEYNOTE-407, 2018 1.52 [0.25; 9.15]
1.52 [0.25 ; 9.15 ] KEYNOTE-407, 2018 1 0% 558 NA not evaluable Pneumonitis AE (grade 3-4)detailed results KEYNOTE-407, 2018 3.07 [0.61; 15.32]
3.07 [0.61 ; 15.32 ] KEYNOTE-407, 2018 1 0% 558 NA not evaluable Pyrexia AE (grade 3-4)detailed results KEYNOTE-407, 2018 1.01 [0.14; 7.20]
1.01 [0.14 ; 7.20 ] KEYNOTE-407, 2018 1 0% 558 NA not evaluable Severe skin reactions AE (grade 3-4)detailed results KEYNOTE-407, 2018 3.04 [0.31; 29.44]
3.04 [0.31 ; 29.44 ] KEYNOTE-407, 2018 1 0% 558 NA not evaluable Thrombocytopenia AE (grade 3-4)detailed results KEYNOTE-407, 2018 1.07 [0.55; 2.08]
1.07 [0.55 ; 2.08 ] KEYNOTE-407, 2018 1 0% 558 NA not evaluable Thyroiditis AE (grade 3-4)detailed results KEYNOTE-407, 2018 2.02 [0.07; 60.40]
2.02 [0.07 ; 60.40 ] KEYNOTE-407, 2018 1 0% 558 NA not evaluable Vomiting AE (grade 3-4)detailed results KEYNOTE-407, 2018 0.16 [0.02; 1.38]
0.16 [0.02 ; 1.38 ] KEYNOTE-407, 2018 1 0% 558 NA not evaluable 0.0 20.0 1.0 relative treatment effect www.metaEvidence.org 2024-11-01 00:12 +01:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 308,164,166,220
- treatments: 847,982,359,575,577,576,869,1081,981,875,505,952,1021,1079,767,1071,1074,873,561